Answers are grounded in this paper and cite their sources.
PURPOSE Outcomes for intermediate-risk (IR) rhabdomyosarcoma (RMS) have remained unchanged for decades. More active chemotherapy regimens, improvements in local control, and the role of maintenance therapy (MTC) remain critical therapeutic questions. RMS13 assessed the safety and efficacy of a risk-adapted local therapy paradigm incorporating proton radiotherapy (RT) and novel MTC comprising sorafenib, bevacizumab, and oral cyclophosphamide (CBvSor) with a vincristine, dactinomycin, and cyclophosphamide (VAC) chemotherapy backbone. PATIENTS AND METHODS We report outcomes for patients with IR RMS enrolled on a multicenter phase II trial evaluating risk-adapted local therapy and MTC. Patients received 12 cycles of VAC followed by four to six cycles of CBvSor in MTC-eligible patients. Tumor status at RT initiation determined RT dose. Five-year event-free survival (EFS), overall survival (OS), disease-free survival (DFS), and local failure (LF) are reported. RESULTS Forty-five patients enrolled, of whom 35 were eligible for MTC at study entry. Twenty-three patients completed at least four cycles of MTC; however, only 18 of 24 completed treatment with all three agents. Five-year EFS and OS were 68.8% (95% CI, 0.57 to 0.84) and 75.2% (95% CI, 0.63 to 0.89), respectively. Among those receiving ≥3 MTC cycles (n = 24), 5-year DFS was 70.8% (95% CI, 0.55 to 0.92). In patients meeting European Pediatric Soft Tissue Sarcoma Group RMS2005 high-risk criteria, DFS was 82.4%. No LF occurred after margin-negative surgery; LF was 4.8% for all patients receiving local control. Five of six patients with fusion-positive N1 disease recurred. The trial closed early due to a prespecified stopping rule, with MTC completion <75%. CONCLUSION Risk-adapted radiation therapy yielded excellent local control in IR RMS. Fusion-positive nodal disease carries a significant negative prognostic value. When ≥3 cycles of CBvSor were administered, improvement in DFS was observed, consistent with other MTC-based studies.
No takes yet. Share an insight, caveat, or question.
Gartrell et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: